First interchangeable biosimilar launches in the US with a tiny discount on list price

Zachary Brennan

Senior Editor

Viatris (formerly known as Mylan and Pfizer’s Upjohn) on Tuesday opened up on the pricing of its interchangeable biosimilar for the insulin Lantus, saying the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

First interchangeable biosimilar launches in the US with a tiny discount on list price

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

SpringWorks lands FDA approval for nerve tumor treatment

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

First in­ter­change­able biosim­i­lar launch­es in the US with a tiny dis­count on list price

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

First interchangeable biosimilar launches in the US with a tiny discount on list price